Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALLI-01 UCART22 in relapsed or refractory CD22-positive B-cell acute lymphoblastic leukemia
2022-502305-15-00Phase 2Completed
- Sponsor
- Cellectis
- Start
- Jan 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 6
01
Overview
Phase 2, open-label trial of UCART22 in B cell acute lymphoblastic leukemia (B-ALL) (4 arms), sponsored by Cellectis. Primary endpoints: Safety in phase 1 dose escalation, Dose-limiting toxicity in phase 1 dose escalation and 3 more. Started Jan 2022; status: completed.
02
Drugs
UCART22
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2022-502305-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502305-15-00.